Impact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine – a pilot study
Authors:
- Proscovia B NamujjuPNProscovia B Namujju
- Emma PajunenEPEmma Pajunen
- Aline Simen-KapeuASAline Simen-Kapeu
- Lea HedmanLHLea Hedman
- Marko MerikukkaMMMarko Merikukka
- Helja-Marja SurcelHSHelja-Marja Surcel
- Reinhard KirnbauerRKReinhard Kirnbauer
- Dan ApterDADan Apter
- Jorma PaavonenJPJorma Paavonen
- Klaus HedmanKHKlaus Hedman
- Matti LehtinenMLMatti Lehtinen
Open Access
- 11 July 2014
- journal article
- research article
- Published by Springer Nature in BMC Research Notes
- Vol. 7 (1) , 445
Abstract
The AS04-adjuvanted bivalent L1 virus-like-particle (VLP) vaccine (Cervarix™) against infection with human papillomavirus (HPV) types 16/18 holds great promise to prevent HPV16/18 infections and associated neoplasias, but it is important to rule out significant co-factors of the neoplasias like smoking. We conducted a pilot study to compare the quantity and quality of HPV16/18 antibody response at baseline and 7 months post vaccination in 104 non-smoking and 112 smoking female participants vaccinated at 0, 1 and 6 months with Cervarix™ (55 and 48 study participants) or with Hepatitis A vaccine (HAVRIX™) (48 and 64 participants, respectively). These 216 women were a sub-sample of 4808 baseline 16- to 17-year old Finnish women initially enrolled in the double-blind, randomized controlled phase III PATRICIA trial. Following end-of-study unblinding in 2009 they were randomly chosen out of all the participants of the three major Finnish PATRICIA study sites in the Helsinki metropolitan area (University of Helsinki, N = 535, and Family Federation Finland, N = 432) and Tampere (University of Tampere, N = 428). Following enrolment, serum samples were collected at month 0 and month 7 post 1st vaccination shot, and were analysed for levels and avidity of IgG antibodies to HPV16 and HPV18 using standard and modified (4 M urea elution) VLP ELISAs. We found that at month 7 post vaccination women who smoked (cotinine level > 20 ng/ml) had levels of anti-HPV16/18 antibodies comparable to those of non-smoking women. Low-avidity HPV16/18 IgG antibodies were observed in 16% of the vaccinated women, and active smoking conferred a three-fold increased risk (95% CI 1.0-9.3) of having the low-avidity antibodies. Our data suggest that while smoking does not interfere with the quantity of vaccine-induced peak IgG levels, it may affect the avidity of IgG induced by HPV16/18 vaccination.Keywords
This publication has 38 references indexed in Scilit:
- Characteristics of HPV-Specific Antibody Responses Induced by Infection and Vaccination: Cross-Reactivity, Neutralizing Activity, Avidity and IgG SubclassesPLOS ONE, 2013
- Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individualsMolecular and Cellular Probes, 2012
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trialThe Lancet Oncology, 2012
- Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccineHuman Vaccines, 2011
- Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine seraVaccine, 2011
- Low avidity of human papillomavirus (HPV) type 16 antibodies is associated with increased risk of low-risk but not high-risk HPV type prevalenceBMC Research Notes, 2011
- Risk of being seropositive for multiple human papillomavirus types among Finnish and Ugandan womenScandinavian Journal of Infectious Diseases, 2010
- Immunogenicity and Safety of Human Papillomavirus (HPV)-16/18 AS04-Adjuvanted Vaccine in Healthy Boys Aged 10–18 YearsJournal of Adolescent Health, 2009
- Is Smoking an Independent Risk Factor for Invasive Cervical Cancer? A Nested Case-Control Study Within Nordic BiobanksAmerican Journal of Epidemiology, 2008
- Smoking is an independent risk factor for oncogenic human papillomavirus (HPV) infections but not for high-grade CINEuropean Journal of Epidemiology, 2007